ISATUXIMAB PLUS CARFILZOMIB AND DEXAMETHASONE VS CARFILZOMIB AND DEXAMETHASONE IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (IKEMA): INTERIM ANALYSIS OF A PHASE 3, RANDOMIZED, OPEN-LABE... by A. Maiolino, P. Moreau, M. Dimopoulos, J. Mikhael, K. Yong, M. Capra, T. Facon, R. Hajek, I. Spicka, M. Risse, G. Asset, S. Macé, T. Martin

Get full text

Isatuximab plus carfilzomib and dexamethasone vs. carfilzomib and dexamethasone in relapsed/refractory multiple myeloma (ikema): interim analysis of a phase 3, randomized, open-lab... by M. Turgut, P. Moreau, M. Dimopoulos, J. Mikhael, K. Yong, M. Capra, T. Facon, R. Hajek, I. Spicka, M. Risse, G. Asset, S. Macé, T. Martin

Get full text

ISATUXIMAB PLUS CARFILZOMIB AND DEXAMETHASONE IN PATIENTS WITH RELAPSED MULTIPLE MYELOMA AND SOFT-TISSUE PLASMACYTOMAS: IKEMA SUBGROUP ANALYSIS by A Maiolino, R Hajek, T Jelinek, P Moreau, T Martin, L Pour, G Mikala, A Symeonidis, S Bringhen, A Rawlings, ML Risse, H Vande-Velde, I Spicka

Get full text

P34 LIGHTHOUSE (OP-108): MELFLUFEN PLUS DARATUMUMAB (DARA) AND DEXAMETHASONE (DEX) VERSUS DARA IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) REFRACTORY TO AN IMMUNOMODULATORY DRUG... by M Mateos, M Szarejko, J Bila, F Schjesvold, I Spicka, V Maisnar, A Jurczyszyn, Z Grudeva-Popova, R Hajek, G Usenko, M Thuresson, S Norin, S Jarefors, P Richardson, L Pour

Get full text

P967: TUMOR BURDEN AS A CRITICAL PROGNOSTIC FACTOR OF PRIMARY EXTRAMEDULLARY DISEASE by M. Vlachová, M. Štork, S. Ševčíková, T. Jelínek, J. Minařík, J. Radocha, P. Krhovská, L. Pospíšilová, I. Špička, J. Straub, P. Pavlíček, A. Jungová, V. Sandecká, V. Maisnar, R. Hájek, L. Pour

Get full text

P1191: ANALYSIS OF PERIPHERAL NEUROPATHY USING CLINICIAN- AND PATIENT-REPORTED OUTCOMES IN THE POLARIX STUDY by M. Trněný, L. Fogliatto, F. Gardner, I. Flinn, J.-F. Larouche, C. Haioun, M. Canales, H. Goto, R. Hajek, G. Salles, J. Qiu, A. Campinha-Bacote, M. Yan, R. Kothari, G. Man, D. Sahin, J. Hirata, C. Lee, H. Tilly, C. Flowers

Get full text

P1714: HEALTHCARE RESOURCE UTILIZATION IN PATIENTS WITH LIGHT CHAIN AMYLOIDOSIS IN EUROPE by A. Jaccard, F. Bridoux, W. Roeloffzen, M. C. Minnema, R. Bergantim, R. Hájek, C. João, M. T. Cibeira, G. Palladini, S. Schönland, G. Merlini, P. Milani, M. A. Dimopoulos, S. Ravichandran, U. Hegenbart, H. Agis, B. Gros, A. Asra, E. Dergarabetian, V. Magarotto, A. Leonidakis, G. Cheliotis, P. Sonneveld, A. Wechalekar, E. Kastritis

Get full text

B03 CARFILZOMIB AND LENALIDOMIDE FOR PRIMARY PLASMA CELL LEUKEMIA: FINAL RESULTS OF THE PROSPECTIVE PHASE 2 EMN12/HOVON-129 STUDY FOR PATIENTS AGED ≥66 YEARS by P. Musto, M.C. Minnema, W.W.H. Roeloffzen, A. Capra, B. van der Holt, A. Juul Vangsted, A. Broyl, F. Schjesvold, T. Lund, T. Silkjaer, R. Benjamin, M. Grasso, K. Lung Wu, J. Caers, M. Cavo, R. Hájek, B. Bruno, A. Gadisseur, G. Pietrantuono, M. Offidani, L. Pour, P. Sonneveld, M. Boccadoro, N. van de Donk

Get full text

B02 CARFILZOMIB AND LENALIDOMIDE-BASED THERAPY FOR THE TREATMENT OF PRIMARY PLASMA CELL LEUKEMIA: RESULTS OF THE FINAL ANALYSIS OF THE PROSPECTIVE PHASE 2 EMN12/HOVON-129 STUDY FOR... by N. van de Donk, M.C. Minnema, B. van der Holt, F. Schjesvold, K.L. Wu, A. Capra, A. Broyl, W.W.H. Roeloffzen, A.P.A. Gadisseur, G. Pietrantuono, L. Pour, V. van der Velden, T. Lund, M. Offidani, M. Grasso, L. Giaccone, M. Cavo, T. Silkjaer, J. Caers, S. Zweegman, R. Hajek, R. Benjamin, A. Vangsted, M. Boccadoro, F. Gay, P. Sonneveld, P. Musto

Get full text